Mabwell (Shanghai) Bioscience Co. has received approval from China's National Medical Products Administration (NMPA) for its clinical trial application for 7MW-3711 for advanced malignant solid tumors.

Mabwell (Shanghai) Bioscience Co. Ltd. has received clearance by China’s National Medical Products Administration (NMPA) for its clinical trial application for 9MW-2921 for advanced solid tumors.

Adcentrx Therapeutics Inc. has received FDA clearance of its IND application for ADRX-0706 for the treatment of select advanced solid tumors.

Salarius Pharmaceuticals Inc. has received FDA clearance of its IND application to initiate a phase I trial with SP-3164 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

280Bio Inc. has received FDA approval of its IND application for the KRAS inhibitor YL-17231. 280Bio will start phase I enrollment in the U.S. in the fourth quarter of this year for the treatment of advanced cancer patients with RAS mutations in their tumors.

Poseida Therapeutics Inc. has received FDA clearance of its IND application for P-CD19CD20-ALLO1, an allogeneic dual chimeric antigen receptor (CAR) T-cell product candidate being developed for relapsed or refractory B-cell malignancies in partnership with F. Hoffmann-La Roche Ltd. The company is actively focused on opening clinical sites for a phase I study in adults with relapsed or refractory B-cell malignancies.

The FDA has cleared C4 Therapeutics Inc.’s IND application for CFT-8919, an orally bioavailable Bidac (bifunctional degradation activating compound) degrader designed to be potent and selective against EGFR L858R for non-small-cell lung cancer (NSCLC).

Skyline Therapeutics (Shanghai) Co. Ltd. has received FDA clearance for its IND application for a phase I/IIa trial of SKG-0106, a one-time intravitreally delivered recombinant adeno-associated virus (AAV) gene therapy for the treatment of neovascular age-related macular degeneration (wet AMD). A global phase I trial will be initiated soon.

Drug Farm has received FDA clearance of its IND application for DF-003, a first-in-class, oral, potent, highly selective ALPK1 inhibitor.